2019 Andrew Sabin Family Fellows share passion for Making Cancer History

Eight awardees receive $100,000 fellowships to fund high-impact cancer research over two years

has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each researcher will receive $100,000 in funding over two years thanks to a $30 million endowment established by the Andrew Sabin Family Foundation, based in East Hampton, New York.

At a luncheon today, the 2019 fellows had the opportunity to thank their benefactor, Andrew Sabin, a member of the MD Anderson Cancer Center Board of Visitors. Members of the 2016, 2017 and 2018 classes of Sabin Family Fellows and faculty mentors also attended.

¡°I look forward each year to meeting the new class of Sabin Family Fellows and experiencing their enthusiasm for unlocking the mysteries of cancer,¡± said Sabin. ¡°My family and I are honored to help launch eight more long and illustrious careers dedicated to advancing MD Anderson¡¯s mission to end cancer.¡±

The Andrew Sabin Family Fellowship Program aims to encourage creativity, innovation and impactful cancer research in the categories of basic science, clinical, physician-scientist, and population and quantitative science. Fellows named in 2018 already have made key discoveries in bladder, pancreatic and gastrointestinal cancers as well as leukemia and glioblastoma.

¡°The ability to recruit and retain the highest caliber of young researchers is critical to the future of our institution,¡± said Peter WT Pisters, M.D., president of MD Anderson. ¡°Sabin Fellowships are among our most valuable tools in helping to recognize and reward tomorrow¡¯s cancer care leaders. I am confident that the foundation¡¯s generosity and vision will have a significant impact on these early career scientists and their efforts to help patients survive this terrible disease.¡±

The 2019 awardees and their areas of focus are:

, associate professor, Thoracic/Head and Neck Medical Oncology: the first CAR-T therapy for small cell lung cancer, in the institution¡¯s first solid tumor CAR-T cell therapy trial

, assistant professor, Clinical Cancer Prevention: study of the intra-tumoral bacteria detected in pancreatic cancer long-term and the use of fecal microbial transplants to improve therapy outcomes.

, assistant professor, Gynecologic Oncology and Reproductive Medicine: improving gynecological genetic testing and risk-reduction interventions in underserved populations

, assistant professor, Radiation Oncology: financial toxicity among patients treated with short-course versus standard adjuvant radiation for early stage breast cancer

, assistant professor, Palliative, Rehabilitation and Integrative Medicine: investigating a personalized proactive technology-enhanced symptom management strategy to provide holistic care for patients on Phase I clinical trials

, assistant professor, Genomic Medicine: the effects of transient inflammation and the role of epithelial memory during the progression of pancreatic ductal adenocarcinoma

, assistant professor, Genomic Medicine: TIM-3 as a potential target for treating peritoneal carcinomatosis in patients with advanced gastric cancer

assistant professor, Gastroenterology, Hepatology and Nutrition: fecal microbiota transplantation to manage immune-mediated colitis, which can be a devastating side effect of cancer immunotherapy